Back

Do hypertensive women with coronary artery disease benefit from lowering systolic blood pressure under 130 mmHg? Long-term mortality in the INternational VErapamil SR-trandolapril STudy (INVEST)

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Hypertension: epidemiology, targets and comorbidities Epidemiology, Prognosis, Outcome ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Ruxandra Sava

Hospital Center of Wallonie Picarde, Tournai (Belgium)

6 More presentations in this session

Presentation thumbnail
2018 ESC/ESH guideline-recommended age categories and intensive blood pressure management in high-risk adults: insights from SPRINT
Doctor M. Pareek (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
All-cause mortality and cardiovascular death according to blood pressure thresholds recommended by ACC/AHA
Doctor G. Joseph (Roskilde, DK)
Abstract Slides
Presentation thumbnail
Association of systolic blood pressure and cardiovascular outcomes at different age groups in the healthy general population: a nationwide prospective cohort study
Doctor M. Jung (Seoul, KR)
Abstract Slides
Presentation thumbnail
Restricted mean survival time analysis to assess efficacy and safety of intensive vs standard blood pressure treatment goals as a function of age: insights from the SPRINT trial
Doctor A. Krishnaswami (San Jose, US)
Abstract Slides
Presentation thumbnail
Optimal blood pressure in diabetic hypertensive patients with overt proteinuria
Professor S. Park (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Hypertension: epidemiology, targets and comorbidities

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources